How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.
Explore this paper's citation graph
Summary
Factors that may influence treatment selection, including patient baseline clinical and demographic characteristics, tumor histology, and biomarkers such as PD-L1 expression and tumor mutation burden, are discussed.
- Type
- review
- Published
- 2019-06-01
- Cited by
- 102
- References
- 95
- Access
- Open access
- OpenAlex
- https://openalex.org/W2923986778
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:85516957
Keywords
Atezolizumab, Durvalumab, Medicine, Nivolumab, Pembrolizumab
References
- PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
- Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.
- CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice.
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- The emerging role of CTLA-4 as an immune attenuator.
- Pembrolizumab for the treatment of non-small-cell lung cancer.
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Neoantigens in cancer immunotherapy
- The PD-1-PD-L pathway in immunological tolerance.
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
- Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)
- Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
- Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Cited by
- Nivolumab plus Carboplatin and Paclitaxel as the First-line Therapy for Advanced Squamous Cell Carcinoma of the Lung with Strong Programmed Death-ligand 1 Expression: A Case Report
- Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC
- New Frontiers for Molecular Pathology
- The relevance of bronchoalveolar lavage fluid analysis for lung cancer patients
- Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold
- Engineering Targeting Materials for Therapeutic Cancer Vaccines
- Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
- The power of immunotherapy plus platinum–based chemotherapy for locally advanced or early stage non-small cell lung cancer
- Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer
- PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC.
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
- Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
- A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors
- Resistance to chemoimmunotherapy in non-small-cell lung cancer
- Genomic and Clinical-Pathologic Characterization of ATM-deficient Prostate Cancer
- Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
- Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes
- Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second‐line pembrolizumab in patients with non‐small‐cell lung cancer
- Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
- The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis
Related papers
- Comparison of Real-world Efficacy and Safety of Atezolizumab and Durvalumab in Combination With Chemotherapy for First-line Treatment of Extensive-stage Small-cell Lung Cancer
- Иммунотерапия уротелиального рака: реалии и перспективы
- Radiologic presentation of non-small cell lung cancer treated with anti-PD-1 therapy.
- Infusion-Related Reactions Subsequent to Avelumab, Durvalumab, and Atezolizumab Administration: A Retrospective Observational Study
- Immunotherapy protocols in lung cancer
- これからの免疫療法の話をしよう 第4回 抗PD‐L1抗体療法―atezolizumab,durvalumab,avelumab
- Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
- Research progress in immunotherapy against PD-1/PD-L1 for advanced urothelial carcinoma
- Single Drug Therapy of PD-1/PD-L1 Checkpoint Inhibitors for Advanced Urothelial Bladder Cancer
- The role of PD-1/PD-L1 inhibitors in the treatment for non-small cell lung cancer (NSCLC)